Singapore markets closed
Straits Times Index
3,230.55 +21.37 (+0.67%) Nikkei
26,781.68 +176.84 (+0.66%) Hang Seng
20,697.36 +581.16 (+2.89%) FTSE 100
7,585.46 +20.54 (+0.27%) BTC-USD
28,720.86 -393.15 (-1.35%) CMC Crypto 200
625.79 -3.71 (-0.59%)
Roche Holding AG (RHHBF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 03:25PM EDT
| Previous close | 392.99 |
| Open | 393.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 392.80 - 393.00 |
| 52-week range | 341.00 - 473.65 |
| Volume | |
| Avg. volume | 746 |
| Market cap | 303.509B |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | 23.32 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 9.97 (2.54%) |
| Ex-dividend date | 17 Mar 2022 |
| 1y target est | N/A |
- Zacks
Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
- Zacks
Roche (RHHBY) Gets EC Approval for Polivy Combination in DLBCL
Roche's (RHHBY) Polivy combination receives the European Commission's approval for patients with previously untreated diffuse large B-cell lymphoma.
- Motley Fool
Why Roche Needs to Invest in At-Home Diagnostics
As the leader in medical diagnostics, Roche (OTC: RHHB.F) acted quickly to deliver valuable COVID-19 screening tests to the marketplace. Assisted by COVID-related sales, its diagnostics division is now delivering stronger growth than its larger pharmaceuticals division. Roche's medical diagnostics division saw strong growth throughout 2021 and into the begining of 2022.
© 2022 Yahoo. All rights reserved.
